Cargando…
507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017
BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811287/ http://dx.doi.org/10.1093/ofid/ofz360.576 |
_version_ | 1783462445471236096 |
---|---|
author | See, Isaac Ansari, Uzma Reses, Hannah Grass, Julian E Epson, Erin Nadle, Joelle Bamberg, Wendy M Janelle, Sarah J Bower, Chris W Jacob, Jesse T Vaeth, Elisabeth Wilson, Lucy E Lynfield, Ruth VonBank, Brittany Snippes Vagnone, Paula Hancock, Emily B Phipps, Erin C Dumyati, Ghinwa Tsay, Rebecca Cassidy, Maureen Kainer, Marion A Mounsey, Jacquelyn Muleta, Daniel Bulens, Sandra N Karlsson, Maria Duffy, Nadezhda Lutgring, Joseph |
author_facet | See, Isaac Ansari, Uzma Reses, Hannah Grass, Julian E Epson, Erin Nadle, Joelle Bamberg, Wendy M Janelle, Sarah J Bower, Chris W Jacob, Jesse T Vaeth, Elisabeth Wilson, Lucy E Lynfield, Ruth VonBank, Brittany Snippes Vagnone, Paula Hancock, Emily B Phipps, Erin C Dumyati, Ghinwa Tsay, Rebecca Cassidy, Maureen Kainer, Marion A Mounsey, Jacquelyn Muleta, Daniel Bulens, Sandra N Karlsson, Maria Duffy, Nadezhda Lutgring, Joseph |
author_sort | See, Isaac |
collection | PubMed |
description | BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in community-dwelling individuals. METHODS: We used 2012–2017 active, laboratory and population-based surveillance data for CRE from CDC’s Emerging Infections Program sites (9 sites by 2017). Cases were the first isolation of Escherichia coli, Klebsiella spp., or Enterobacter spp. from a normally sterile body specimen or urine in a surveillance site resident meeting a CRE phenotype (figure) in a 30 day period. Epidemiologic data were obtained from chart review. Cases were community-associated (CA) if not isolated after the first three days of a hospital stay; without inpatient healthcare, dialysis, or surgery in the year prior; and without indwelling medical devices within two days prior to culture. A convenience sample of isolates was tested at CDC by real-time PCR to detect bla(KPC), bla(NDM), bla(OXA-48-like), bla(VIM), or bla(IMP). RESULTS: Of 4023 CRE cases, 699 (17%) were CA, from which 297 isolates were tested; 20 (7%) were CP-CRE, from 18 patients (2 had repeat isolation of the same gene/species). The median age was 68 years (range: 33–91), and 14 (78%) were female. Patients were from 7 sites (range: 1–4/site). Their CP-CRE (10 bla(KPC), 6 bla(NDM), and 2 bla(OXA-48-like)) were from three species (10 K. pneumoniae, 6 E. coli, 2 E. cloacae) and isolated from urine (n = 16) and blood (n = 2). Among those with CP-CRE from urine, 12 (75%) had clinical diagnoses of urinary tract infections and the rest had no infection documented. Overall, 7 (39%) were admitted to a hospital within 30 days of culture; none died during hospitalization. Most (n = 13; 72%) had underlying medical comorbidities, most commonly urinary tract abnormalities (n = 5; 28%) and diabetes mellitus (n = 5; 28%). Three (17%) had international travel within two months prior to culture. CONCLUSION: CA CP-CRE were found in most surveillance sites but are rare, occurring primarily in older patients with underlying medical conditions. Patient interviews are planned to determine whether CA CP-CRE may be associated with distant or undocumented healthcare exposures. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6811287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68112872019-10-29 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 See, Isaac Ansari, Uzma Reses, Hannah Grass, Julian E Epson, Erin Nadle, Joelle Bamberg, Wendy M Janelle, Sarah J Bower, Chris W Jacob, Jesse T Vaeth, Elisabeth Wilson, Lucy E Lynfield, Ruth VonBank, Brittany Snippes Vagnone, Paula Hancock, Emily B Phipps, Erin C Dumyati, Ghinwa Tsay, Rebecca Cassidy, Maureen Kainer, Marion A Mounsey, Jacquelyn Muleta, Daniel Bulens, Sandra N Karlsson, Maria Duffy, Nadezhda Lutgring, Joseph Open Forum Infect Dis Abstracts BACKGROUND: Carbapenemase-producing (CP-) carbapenem-resistant Enterobacteriaceae (CRE) have been almost exclusively linked to extensive healthcare exposure and are of significant concern due to limited treatment options and potential for plasmid-mediated spread of resistance. We report on CP-CRE in community-dwelling individuals. METHODS: We used 2012–2017 active, laboratory and population-based surveillance data for CRE from CDC’s Emerging Infections Program sites (9 sites by 2017). Cases were the first isolation of Escherichia coli, Klebsiella spp., or Enterobacter spp. from a normally sterile body specimen or urine in a surveillance site resident meeting a CRE phenotype (figure) in a 30 day period. Epidemiologic data were obtained from chart review. Cases were community-associated (CA) if not isolated after the first three days of a hospital stay; without inpatient healthcare, dialysis, or surgery in the year prior; and without indwelling medical devices within two days prior to culture. A convenience sample of isolates was tested at CDC by real-time PCR to detect bla(KPC), bla(NDM), bla(OXA-48-like), bla(VIM), or bla(IMP). RESULTS: Of 4023 CRE cases, 699 (17%) were CA, from which 297 isolates were tested; 20 (7%) were CP-CRE, from 18 patients (2 had repeat isolation of the same gene/species). The median age was 68 years (range: 33–91), and 14 (78%) were female. Patients were from 7 sites (range: 1–4/site). Their CP-CRE (10 bla(KPC), 6 bla(NDM), and 2 bla(OXA-48-like)) were from three species (10 K. pneumoniae, 6 E. coli, 2 E. cloacae) and isolated from urine (n = 16) and blood (n = 2). Among those with CP-CRE from urine, 12 (75%) had clinical diagnoses of urinary tract infections and the rest had no infection documented. Overall, 7 (39%) were admitted to a hospital within 30 days of culture; none died during hospitalization. Most (n = 13; 72%) had underlying medical comorbidities, most commonly urinary tract abnormalities (n = 5; 28%) and diabetes mellitus (n = 5; 28%). Three (17%) had international travel within two months prior to culture. CONCLUSION: CA CP-CRE were found in most surveillance sites but are rare, occurring primarily in older patients with underlying medical conditions. Patient interviews are planned to determine whether CA CP-CRE may be associated with distant or undocumented healthcare exposures. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811287/ http://dx.doi.org/10.1093/ofid/ofz360.576 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts See, Isaac Ansari, Uzma Reses, Hannah Grass, Julian E Epson, Erin Nadle, Joelle Bamberg, Wendy M Janelle, Sarah J Bower, Chris W Jacob, Jesse T Vaeth, Elisabeth Wilson, Lucy E Lynfield, Ruth VonBank, Brittany Snippes Vagnone, Paula Hancock, Emily B Phipps, Erin C Dumyati, Ghinwa Tsay, Rebecca Cassidy, Maureen Kainer, Marion A Mounsey, Jacquelyn Muleta, Daniel Bulens, Sandra N Karlsson, Maria Duffy, Nadezhda Lutgring, Joseph 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title | 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title_full | 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title_fullStr | 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title_full_unstemmed | 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title_short | 507. Epidemiology of Community-Associated Carbapenemase + Producing Carbapenem-Resistant Enterobacteriacae Identified from the Emerging Infections Program, 2012–2017 |
title_sort | 507. epidemiology of community-associated carbapenemase + producing carbapenem-resistant enterobacteriacae identified from the emerging infections program, 2012–2017 |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811287/ http://dx.doi.org/10.1093/ofid/ofz360.576 |
work_keys_str_mv | AT seeisaac 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT ansariuzma 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT reseshannah 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT grassjuliane 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT epsonerin 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT nadlejoelle 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT bambergwendym 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT janellesarahj 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT bowerchrisw 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT jacobjesset 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT vaethelisabeth 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT wilsonlucye 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT lynfieldruth 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT vonbankbrittany 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT snippesvagnonepaula 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT hancockemilyb 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT phippserinc 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT dumyatighinwa 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT tsayrebecca 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT cassidymaureen 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT kainermariona 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT mounseyjacquelyn 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT muletadaniel 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT bulenssandran 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT karlssonmaria 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT duffynadezhda 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 AT lutgringjoseph 507epidemiologyofcommunityassociatedcarbapenemaseproducingcarbapenemresistantenterobacteriacaeidentifiedfromtheemerginginfectionsprogram20122017 |